ADCT news & sentiment — ADC Therapeutics SA

MAR 14·MSNMed

ADC Therapeutics signals ZYNLONTA peak revenue potential of $600M–$1B in U.S. with expanded clinical milestones

ADC Therapeutics announced that ZYNLONTA, its approved drug for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), has a projected peak revenue potential in the U.S. of $600 million to $1 billion. The company also presented new clinical data and outlined plans for further development, including combination therapies and studies in new indications. These initiatives aim to expand ZYNLONTA's market reach and patient population.

MAR 6·TradingView

ADC Therapeutics SA expected to post a loss of 27 cents a share - Earnings Preview

ADC Therapeutics SA (ADCT) is projected to report a loss of 27 cents per share in its upcoming earnings announcement. This information is based on an earnings preview from Reuters. Further details likely require logging in or creating an account on the platform where the article is hosted.

MAR 3·Stock Titan

ADC Therapeutics sets March 10 call on 2025 results and operations

ADC Therapeutics (NYSE: ADCT) will host a conference call and live webcast on March 10, 2026, at 8:30 a.m. EDT to report its fourth quarter and full-year 2025 financial results and provide operational updates. The company's stock, ADCT, was up 1.95% recently, while historically, similar earnings call announcements have led to a modest average next-day decrease of 4.5% in stock price. Investors can register in advance for the call, which will include details on financial performance for the period ended December 31, 2025, and the webcast archive will be available for 30 days.

$ADCT

ADC Therapeutics signals ZYNLONTA peak revenue potential of $600M–$1B in U.S. with expanded clinical milestones

ADC Therapeutics SA expected to post a loss of 27 cents a share - Earnings Preview

ADC Therapeutics sets March 10 call on 2025 results and operations

News on $ADCT